X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs DIVIS LABORATORIES - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD DIVIS LABORATORIES BIOCON LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 96.0 38.4 249.8% View Chart
P/BV x 8.1 6.2 130.6% View Chart
Dividend Yield % 0.1 0.7 19.8%  

Financials

 BIOCON LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
DIVIS LABORATORIES
Mar-18
BIOCON LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1881,142 104.0%   
Low Rs305533 57.2%   
Sales per share (Unadj.) Rs68.7146.6 46.9%  
Earnings per share (Unadj.) Rs7.633.0 22.9%  
Cash flow per share (Unadj.) Rs14.038.4 36.4%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.11.2 11.2%  
Book value per share (Unadj.) Rs86.3222.8 38.7%  
Shares outstanding (eoy) m600.00265.47 226.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.95.7 190.1%   
Avg P/E ratio x98.925.3 390.0%  
P/CF ratio (eoy) x53.421.8 245.0%  
Price / Book Value ratio x8.63.8 230.0%  
Dividend payout %13.230.3 43.7%   
Avg Mkt Cap Rs m447,900222,318 201.5%   
No. of employees `0006.110.8 57.1%   
Total wages/salary Rs m9,3114,561 204.2%   
Avg. sales/employee Rs Th6,705.83,616.0 185.5%   
Avg. wages/employee Rs Th1,514.2423.8 357.3%   
Avg. net profit/employee Rs Th736.9814.9 90.4%   
INCOME DATA
Net Sales Rs m41,23438,915 106.0%  
Other income Rs m2,0621,134 181.8%   
Total revenues Rs m43,29640,049 108.1%   
Gross profit Rs m8,29112,617 65.7%  
Depreciation Rs m3,8511,425 270.3%   
Interest Rs m61513 4,624.1%   
Profit before tax Rs m5,88712,313 47.8%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5693,543 44.3%   
Profit after tax Rs m4,5318,770 51.7%  
Gross profit margin %20.132.4 62.0%  
Effective tax rate %26.728.8 92.6%   
Net profit margin %11.022.5 48.8%  
BALANCE SHEET DATA
Current assets Rs m41,48645,351 91.5%   
Current liabilities Rs m21,4136,507 329.1%   
Net working cap to sales %48.799.8 48.8%  
Current ratio x1.97.0 27.8%  
Inventory Days Days64127 50.5%  
Debtors Days Days9495 99.0%  
Net fixed assets Rs m50,66121,160 239.4%   
Share capital Rs m3,000531 565.1%   
"Free" reserves Rs m48,80858,625 83.3%   
Net worth Rs m51,80859,156 87.6%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89767,832 147.3%  
Interest coverage x10.6926.8 1.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.6 71.9%   
Return on assets %5.212.9 39.8%  
Return on equity %8.714.8 59.0%  
Return on capital %9.620.8 46.2%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m12,05832,359 37.3%   
Fx outflow Rs m7,3489,042 81.3%   
Net fx Rs m4,71023,317 20.2%   
CASH FLOW
From Operations Rs m6,6217,759 85.3%  
From Investments Rs m-6,840-4,783 143.0%  
From Financial Activity Rs m-2,397-3,142 76.3%  
Net Cashflow Rs m-2,612-166 1,573.5%  

Share Holding

Indian Promoters % 40.4 52.0 77.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.8 71.2%  
FIIs % 10.7 19.0 56.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.2 115.7%  
Shareholders   109,995 31,796 345.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 25, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS